From South China Morning Post
Akeso shares plummet as Chinese firm’s cancer drug ivonescimab faces FDA setback
Shares in Hong Kong-listed Akeso plunged as much as 31.8 per cent on Monday morning after the US Food and Drug Administration (FDA) rejected its cancer drug application, raising investor worries over...